The US Food and Drug Administration has rejected a new drug aimed at treating generalised anxiety disorder (GAD), it has been revealed.
Healthcare giant Pfizer said in a statement it was disappointment by the decision of the FDA over its Lyrica drug.
In a letter explaining the decision to reject the treatment, the FDA said: “The data contained in the (new drug application) were insufficient to support approval.”
Pfizer said it would be working with the agency in order to progress with the treatment in the future.
The company is still awaiting a response to an application over whether Lyrica could be used alongside other medications to treat GAD.
Copyright © Press Association 2009